Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.47
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.47
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.85 - C$4.95
Previous CloseN/A
Volume1.00K
Average Volume (3M)3.78K
Market Cap
C$45.92M
Enterprise ValueC$12.33M
Total Cash (Recent Filing)C$1.83M
Total Debt (Recent Filing)C$696.00K
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding10,436,313
10 Day Avg. Volume5,604
30 Day Avg. Volume3,778
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMedicure’s conservative capital structure limits near-term financial risk and preserves flexibility for operations, commercialization investment, or strategic initiatives. Low debt also reduces interest burden and refinancing exposure, providing a stronger foundation if operating performance improves.
Revenue Base GrowthThe company continues to expand its revenue base despite current profitability pressure, indicating ongoing demand for its marketed products and commercialization platform. Sustained top-line growth could improve operating leverage over time if Medicure can align expenses and product economics with sales.
Specialty Cardiovascular FocusA focused cardiovascular portfolio and established commercialization activity in the United States and Canada give Medicure a defined therapeutic and geographic market position. Concentrated expertise can support targeted sales execution, prescriber relationships, and deeper product adoption over the medium term.
Bears Say
Persistent Net LossesMedicure’s revenue base is not currently supporting a profitable operating structure. Continued net losses and negative operating margins can weaken retained capital, constrain investment capacity, and make future earnings dependent on a material improvement in sales productivity, product mix, or cost control.
Negative Cash GenerationThe business is presently consuming cash rather than funding itself through operations, reducing its ability to reinvest without drawing on liquidity or external capital. If negative cash generation persists, financial flexibility may narrow despite the company’s low debt burden and could constrain commercialization efforts.
Margin DeteriorationThe decline in gross margin indicates that recent revenue growth is producing less contribution than in prior periods, potentially reflecting an unfavorable product mix or higher costs. Unless margins recover, additional sales may not translate efficiently into earnings or cash flow, prolonging the current profitability strain.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.85 and its highest was C$4.95 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$45.92M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Nov 25, 2026 which is in 33 days.
How were Medicure Inc’s earnings last quarter?
Medicure Inc released its earnings results on Aug 14, 2026. The company reported -C$0.137 earnings per share for the quarter.
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Medicure Inc reported an EPS of -C$0.137 in its last earnings report. Following the earnings report the stock price went up 2.206%.
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―